Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. All podium presentation sessions will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time (U.S. ET) specified in the program. Poster presentations will not be available for viewing on-demand.

Program in progress.

*-Short talk from proffered abstract

Wednesday, October 22

• Educational Session 1: Phase I Novel Clinical Trial Designs
• Educational Session 2: How to Approach Project Optimus?
• Welcome and Opening Keynote Lectures

*-Short talk from proffered abstract

Registration

12-7 p.m. | Lobby D

Educational Session 1: Phase I Novel Clinical Trial Designs

2-3:30 p.m. | Level 3, Ballroom AB

Session Cochairs: Christophe Massard, Gustave Roussy, Rennes, France, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

• 2 p.m. | Strategies to integrate liquid and tumor biopsies in phase I trials
  Christophe Massard
• 2:25 p.m. | Moving phase 1 trials to first-line metastatic disease: Challenges and opportunities
  Anna Farago, Amgen Oncology, Thousand Oaks, California
• 2:45 p.m. | Project Optimus: Novel Phase I clinical trial designs
  Timothy A. Yap
• 3:05 p.m. | Q&A / Discussion

Break

3:30-3:45 p.m.

Educational Session 2: How to Approach Project Optimus?

3:45-5:15 p.m. | Level 3, Ballroom AB

Session Cochairs: Deepa Subramaniam, AstraZeneca, Gaithersburg, Maryland, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

• 3:50 p.m. | Achieving dosage optimization for combination regimens
  Deepa Subramaniam
• 4:10 p.m. | Project Optimus challenges from the biotech perspective
  Harpreet Singh, Precision for Medicine, Bethesda, Maryland
• 4:30 p.m. | Panel Discussion
  Robert Doebele, Boundless Bio, San Diego, California
  Anna Farago, Amgen Oncology, Thousand Oaks, California
  Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut

Break 

5:15-5:30 p.m.

Welcome and Opening Keynote Lectures

5:30-7:15 p.m. | Level 3, Ballroom AB

• 5:30 p.m. | Welcome from Scientific Committee Cochairs
  Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts
  Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
• 5:40 p.m. | Introduction of Keynote Speaker
  Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts
• 5:45 p.m. | Keynote Speaker
  Unlocking the potential of bispecific t-cell engagers in solid tumors
  Jean-Charles Soria, Amgen Oncology, Thousand Oaks, California
• 6:15 p.m. | Introduction of Keynote Speaker
  Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
• 6:20 p.m. | Keynote Speaker
  The coming renaissance of cancer immunotherapy
  Ira Mellman, Parker Institute for Cancer Immunotherapy, San Francisco, California
• 6:50 p.m. | Discussion / Q&A

Opening Reception

7:15-9:30 p.m. | Level 3, Boylston Street Hallway